Kevin Finney

TARIS BioMedical LLC operates as a clinical-stage pharmaceutical company. It specializes in urology, continuous local dosing, bladder diseases, oncology, voiding dysfunction. The company was founded by Robert S. Langer Jr., Christine Bunt, and Michael J. Cima in 2008 and is headquartered in Lexington, MA.

Eirion Therapeutics, Inc. is a clinical stage biopharmaceutical company that is developing prescription products for aesthetic dermatology. The company is based in Woburn, MA. The company has a pipeline of products that focus on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients. The company was founded in 2016. Jonathan T. Edelson has been the CEO of the company since 2016.

Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA.

Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million.

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.